7210 Wareham Drive, Tampa, FL 33647
May 1, 2025 The National Consumers League (NCL) – a leading non-profit fighting fraud in the marketplace – today released a white paper as a blueprint for policy changes to combat the flood of false information circulating online about GLP-1 products and launched an ambitious national anti-disinformation effort called the Weight Truth with the online […]
April 12, 2025 We noticed a post on Instagram today that pitches a company that will set up a medical weight loss program, using GLP-1 drugs for gyms. We shouldn’t be surprised. Everyone else has entered the GLP-1 gold rush, including med spas, so why not gyms as well? The company offering this “opportunity” is
Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded Read More »
April 9, 2025 (Reuters) – WW International may be preparing to file for bankruptcy in the coming months as part of a plan to hand control of the business to its creditors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Shares of the company tumbled nearly 59% to 18 cents
Weight Watchers Prepares for Possible Bankruptcy Filing Read More »
March 5, 2025 Weight loss drugs (GLP-1s) have soared in popularity over the last two years, with about 12% of American adults reporting that they’ve used a medication like Ozempic, Wegovy or Mounjaro to slim down. That’s a big slice of the population — and new research shows that being on these medications influences what
GLP-1 Drugs Are Affecting Consumers’ Food Spending Habits Read More »
Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0
Medifast Reports Q4 and Full Year 2024 Results Read More »
January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the
The Party Is Almost Over for GLP-1 Compounders Read More »
Dec. 20, 2024 The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. Zepbound is FDA-approved to treat obesity and Mounjaro is approved for diabetes. They
FDA Says Shortage Is Over, Compounders Have 60-90 Days Read More »
Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists
Zepbound Beats Wegovy for Weight Loss Read More »
Nov. 6, 2024 WW (Weight Watchers) reported results for the 3rd quarter 2024 today. “For over six decades, Weight Watchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to
Weight Watchers Reports 3rd Quarter Results Read More »
Nov. 4, 2024 Medifast reported Q3 results today. CEO Dan Chard said: “With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.” Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672
Medifast Reports 3rd Quarter Results Read More »